Company profile: PlasmidFactory
1.1 - Company Overview
Company description
- Provider of contract manufacturing for plasmid and minicircle DNA, serving cancer research, gene and cell therapy, CAR T-cell development, and vaccination. Offerings include plasmid DNA production, minicircle DNA vectors, capillary gel electrophoresis quality control, GMP-compliant long-term DNA storage, and R&D services in plasmid and minicircle DNA technologies.
Products and services
- Minicircle DNA: Engineers and produces minicircle DNA vectors for gene therapy and CAR T cell production, contract-manufactured with vector-based design for cell and gene applications
- Plasmid DNA: Produces plasmid DNA for various applications including gene therapy and genetic vaccination, contract-manufactured and serving customers in cancer research, gene and cell therapy, CAR T-cell development, and vaccination
- DNA Storage Service: Delivers long-term storage of plasmid DNA under GMP conditions, GMP-compliant retention for clients in gene and cell therapy, CAR T-cell development, cancer research, and vaccination
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PlasmidFactory
Base Genomics
HQ: United Kingdom
Website
- Description: Provider of epigenetics technologies focused on developing a blood test for early-stage cancer and minimal residual disease, based on TAPS (TET-assisted pyridine borane sequencing), a new invention to sequence DNA methylation developed at the Ludwig Institute for Cancer Research Branch at the University of Oxford, using a novel chemical reaction that converts methylated cytosine to thymine under mild conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Base Genomics company profile →
Rubicon Genomics
HQ: United States
Website
- Description: Provider of advances in translating human genetics “laboratory knowledge” into practical medicine applications; founded in 2000 by University of Michigan faculty Dr. John Langmore and Dr. Vladimir Makarov, with roots in Michigan.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rubicon Genomics company profile →
GenArraytion
HQ: United States
Website
- Description: Provider of medical diagnostics products and services for tick- and mosquito-borne disease and surveillance, epidemiology and source tracking, food and water testing, biodefense and environmental monitoring, including MultiFLEX Bioassays and Sniper Sequencing genotyping services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenArraytion company profile →
Diagnovus
HQ: United States
Website
- Description: Provider of innovative molecular diagnostics delivering individualized genetic information to better inform physicians, patients, and families facing difficult disease prospects, improving patient health and the quality of treatment decisions; founded in 2011 and based in Nashville, TN.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnovus company profile →
Treos Bio
HQ: United Kingdom
Website
- Description: Provider of computational immunology solutions that predict in silico likely responders to cancer immunotherapies and design next-generation targeted immunotherapies tailored to patient genetics; offers PolyPEPI1018 for metastatic colorectal cancer (developed without need for tumor biopsy), PEPI Panel to create personalized therapies based on tumor type and HLA genotype, PolyPEPI-SCoV-2 preventive vaccine, and PEPI Test predicting peptide-specific T cell responses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Treos Bio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PlasmidFactory
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PlasmidFactory
2.2 - Growth funds investing in similar companies to PlasmidFactory
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PlasmidFactory
4.2 - Public trading comparable groups for PlasmidFactory
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →